

Pompe Disease Market Share , Trends, Growth Factors, Future scope, Top Key Players with Revenue Analysis

Increasing developments in the gene therapy and enzyme replacement therapies are driving factors for the growth of Pompe disease market.

HYDERABAD, TELANGANA, INDIA, February 13, 2023 /EINPresswire.com/ -- [Pompe Disease Market](#) size is \$1,277Billion in 2019, growing at a CAGR of 3.7% during the forecast period 2020-2025. Pompe disease is also known as GAA deficiency or type II glycogen storage disease (GSD). It is a genetic disorder in which complex sugar called glycogen builds up metabolic deficiency of an enzyme called Acid Alpha in the body. This buildup occurs in organs break down. The additional glycogen builds up in heart and other tissues, which causes trouble muscle weakness and trouble breathing, that can lead to premature death in the



Market Research Reports, Business Consulting
Services & Analytics

Click here to browse the complete report summary:

<https://www.industryarc.com/Report/17417/pompe-disease-market.html>

Key Takeaways

1. Increased research in the field of Pompe Disease is set to propel the growth of the market.
2. Increasing developments in the gene therapy and enzyme replacement therapies are driving factors for the growth of Pompe disease market.
3. Europe region is estimated to record the fastest growth rate during the forecast period 2020-

2025.

Interested in knowing more relevant information? Click here:

<https://www.industryarc.com/pdfdownload.php?id=17417>

Segment Analysis

1. In 2019, Enzyme Replacement Therapy (ERT) segment dominated the Pompe Disease Market in terms of revenue is estimated to grow at a CAGR of 3.0%. Enzyme Replacement Therapy is used to increase the levels of GAA in the body and reduce the accumulation of glycogen inside cells. It also helps maintain muscle function and improve patients' quality of life. Lumizyme (alglucosidase alfa) is an FDA approved drug for Enzyme Replacement Therapy abetting towards the market's growth.
2. In 2019, the North America region dominated Pompe Disease Market in terms of revenue with a market share of 39% owing towards owing to the presence of established payers and an increase in the number of Pompe disease patients in the region.
3. Government has taken initiatives to promote the healthcare expenditure, growing awareness among patients regarding rare disorders in this region are key factors in the growth of the Pompe Disease market.
4. Europe is estimated to record the fastest growth rate during the forecast period 2020-2025.

Competitive Landscape:

The top 5 players in the Pompe Disease Industry are -

1. Amicus Therapeutics
2. Sanofi
3. Audentes Therapeutics
4. Valerion Therapeutics
5. Centogene

Click on the following link to buy the Pompe Disease Market Report:

<https://www.industryarc.com/reports/request-quote?id=17417>

Why Choose IndustryARC?

IndustryARC is one of the leading market research and consulting firms in the world. It produces over 500 unique market reports annually. If you are looking for a detailed overview of a particular market, you can simply connect with the team at IndustryARC. You can not only buy your preferred market report from the website but also get personalized assistance on specific

reports.

Contact Us:

Mr. Venkat Reddy

IndustryARC

Email: venkat@industryarc.com, sales@industryarc.com

USA: (+1) 970-236-3677, (+1) 815-656-4596

IND: (+91) 40-485-49062

Venkat Reddy

IndustryARC

+1 614-588-8538

venkat@industryarc.com

Visit us on social media:

[Facebook](#)

[Twitter](#)

[LinkedIn](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/616750581>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2023 Newsmatics Inc. All Right Reserved.